WHEN DO YOU PLAN TO GET
YOUR NEXT CHOLESTEROL TEST?

ESPERION Q2 2022 EARNINGS PRESENTATION

AUGUST 2, 2022

FORWARD-LOOKNG STATEMENTS & DISCLOSURES

This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the impact of the ongoing COVID-19 pandemic on our business, revenues, results of operations and financial condition, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

WHEN DO YOU PLAN TO GET
YOUR NEXT CHOLESTEROL TEST?

BUSINESS OVERVIEW

SHELDON KOENIG, PRESIDENT AND CEO

Q2 2022 & RECENT HIGHLIGHTS

- CLEAR Outcomes trial achieved 100% MACE-4 Accumulation
  - ➢ Study close-out underway and topline results expected Q1 2023
- Q2 2022 Operational Expenses were down $9.4 million Y/Y
- U.S net product revenue of NEXLETOL® and NEXLIZET® recognized growth of approximately 28% Y/Y to $13.6 million in Q2 2022
- Retail Prescription Equivalents (RPE) grew +5.9% quarter over quarter
- Scientific Advisory Board (SAB) of leading experts announced, with R&D Day planned for November 9, 2022
- Ended Q2 2022 with $235.8 million in cash, cash equivalents, restricted cash and investment securities

Picture: Heart Disease and Stroke Statistics-2019 Update, Source: American Heart Association Published: Jan. 31, 2019

ESPERION

FOCUS ON CLOSING OUT CLEAR OUTCOMES

ACHIEVED 100% MACE-4 ACCUMULATION; TOPLINE RESULTS Q1 2023

CLEAR Outcomes

- Global 14,014-patient randomized, double-blind, placebo-controlled clinical trial
  - One of largest and longest of any non-statin trial; conducted in the modern-day medical environment
- Unique patient population with high unmet need:
    - Established ASCVD or at high-risk of developing ASCVD
    - LDL-C ≥100 mg/dL on maximally-tolerated lipid-lowering therapy including no statin
- Primary outcome (MACE-4): composite of the time to first cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization
- Event-driven trial
    - >1,620 MACE-4 events achieved
    - > 810 hard ischemic events (MACE-3) cardiovascular death, nonfatal myocardial infarction or nonfatal stroke achieved
    - Median treatment duration of 3.5 years achieved

ESPERION

SCIENTIFIC ADVISORY BOARD APPOINTED

RENOWNED SCIENTISTS TO GUIDE PIPELINE DEVELOPMENT

Peter Libby, MD, FAHA
Board Co-Chair, Brigham and Women's Hospital

JoAnne Foody, MD, FACC, FAHA
Board Co-Chair, Esperion CMO

Jeffrey Bender, MD
Yale School of Medicine

Erin Bohula May, MD DPhil
Brigham and Women's Hospital

Karin Bornfeldt, PhD, FAHA
University of Washington

Dennis Bruemmer, MD, PhD
Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute

David Cohen, MD, PhD
Brigham and Women's Hospital

Gabrielle Fredman, PhD
Albany Medical College

Marilyn Glassberg, MD
Loyola University of Chicago Stritch School of Medicine

R. Preston Mason, MBA, PhD
Brigham and Women's Hospital

Pradeep Natarajan, MD, MMsC
Massachusetts General Hospital

Gerald Shulman, MD, PhD, MACP, MACE, FRCP
Yale

WHEN DO YOU PLAN TO GET
YOUR NEXT CHOLESTEROL TEST?

FINANCIAL UPDATE

SHELDON KOENIG, PRESIDENT AND CEO

U.S REVENUE OF $13.6 MILLION

FOCUSED ON DRIVING CONSISTENT GROWTH AS WE APPROACH CVOT RESULTS

Quarterly Franchise RPE Trend



Weekly Franchise RPE Trend Since Launch [1]



1. Through July 1, 2022

*Based on Symphony data

RPE = Retail Prescription Equivalence; derived by normalizing the extended units Rx (no. of tablets) to determine the 30-day supply equivalent

ESPERION

FINANCIAL STRENGTH TO DELIVER GROWTH

CASH RUNWAY SUFFICIENT BEYOND CLEAR OUTCOMES READ-OUT

$13.6 M Q2 2022 U.S. Product Revenue

$235.8 M Q2 2022 Cash, Cash Equivalents, Restricted Cash & Investment Securities Available-for-Sale [1]

>$1.2 B Potential Future Ex-U.S. Collaboration Milestones from Daiichi Sankyo & Otsuka

Key Financial Data

FY 2022 R&D Guidance	**$100 - $110 Million**
FY 2022 SG&A Guidance	**$120 - $130 Million**
FY 2022 Op Ex Guidance [2]	**$220 - $240 Million**
Q2 2022 Common Shares Outstanding [3]	**64.6 Million**

1. Includes $50M of restricted cash
2. Includes $25M of anticipated non-cash stock-based compensation expense
3. After accounting for 2.0 million treasury shares to be purchased in the $50M prepaid forward transaction as part of the November 2020 convertible debt financing

ESPERION

THANK YOU

IMPORTANT SAFETY INFORMATION



NEXLETOL® SAFETY PROFILE

- Contraindications: None
- Warnings and Precautions:
  - Hyperuricemia: NEXLETOL may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout.
  - Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture.
- Avoid concomitant use with simvastatin (>20 mg/day) or pravastatin (>40 mg/day) due to increased risk of adverse events.
- Most common adverse reactions in ≥2% of patients taking NEXLETOL and more frequently than placebo:
  - Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes
- Adverse events reported less frequently but still more often than in placebo included benign prostatic hyperplasia and atrial fibrillation

This summary does not reflect the full safety profile – please see https://pi.esperion.com/nexletol/nexletol-pi.pdf

NEXLIZET® SAFETY PROFILE

- Contraindication: Known hypersensitivity to ezetimibe tablets
- Warnings and Precautions:
  - Hyperuricemia: Bempedoic acid may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout.
  - Tendon Rupture: Bempedoic acid is associated with an increased risk of tendon rupture.
- Avoid concomitant use with simvastatin (>20 mg/day) or pravastatin (>40 mg/day). Monitor cyclosporine concentrations with cyclosporine. If cholelithiasis is suspected in a patient receiving fenofibrate, consider alternative lipid-lowering therapy.
- Most common adverse reactions in >2% of patients taking NEXLIZET and more frequently than placebo:
  - Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, elevated liver enzymes, diarrhea, fatigue, influenza, sinusitis, and arthralgia
- Adverse events reported less frequently but still more often than in placebo included benign prostatic hyperplasia and atrial fibrillation

This summary does not reflect the full safety profile - see https://pi.esperion.com/nexlizet/nexlizet-pi.pdf

ANTICIPATING INCREASED FOCUS ON CARDIOVASCULAR DISEASE PREVENTION

Cardiovascular disease was worsened by the COVID-19 pandemic[1,2]

- 4.1% increase in age-adjusted death rate from heart disease between 2019 and 2020[3]
- COVID-19 survivors across the globe have been left with a 63% higher risk for heart attack and a 52% higher risk of stroke
- Risk of cardiovascular problems was increased for all people, no matter age, gender, or health status

ESPERION is a leading biotech in cardiovascular disease prevention

- Increasing awareness of NEXLETOL® and NEXLIZET® today
- Completing the CLEAR Outcomes trial
- Continuing to progress our pipeline that includes an oral PCSK9 inhibitor and an ACL inhibitor platform which will participate in a market valued at over $11 billion in 2026[4]

1. As COVID-19 Drags on, the Cardiology Fallout May Haunt for Years | tctmd.com
2. https://www.science.org/content/article/covid-19-takes-serious-toll-heart-health-full-year-after-recovery
3. JAMA Health Forum – Health Policy, Health Care Reform, Health Affairs | JAMA Health Forum | JAMA Network
4. https://s21.q4cdn.com/488056881/files/doc_events/2022/04/CV-Investor-Event_Final.pdf

ESPERION